163 related articles for article (PubMed ID: 35459873)
1. Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma.
Wong J; Gruber E; Maher B; Waltham M; Sabouri-Thompson Z; Jong I; Luong Q; Levy S; Kumar B; Brasacchio D; Jia W; So J; Skinner H; Lewis A; Hogg SJ; Vervoort S; DiCorleto C; Uhe M; Gamgee J; Opat S; Gregory GP; Polekhina G; Reynolds J; Hawkes EA; Kailainathan G; Gasiorowski R; Kats LM; Shortt J
Leukemia; 2022 Jun; 36(6):1654-1665. PubMed ID: 35459873
[TBL] [Abstract][Full Text] [Related]
2. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial.
Garcia-Manero G; Roboz G; Walsh K; Kantarjian H; Ritchie E; Kropf P; O'Connell C; Tibes R; Lunin S; Rosenblat T; Yee K; Stock W; Griffiths E; Mace J; Podoltsev N; Berdeja J; Jabbour E; Issa JJ; Hao Y; Keer HN; Azab M; Savona MR
Lancet Haematol; 2019 Jun; 6(6):e317-e327. PubMed ID: 31060979
[TBL] [Abstract][Full Text] [Related]
3. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.
Kantarjian HM; Roboz GJ; Kropf PL; Yee KWL; O'Connell CL; Tibes R; Walsh KJ; Podoltsev NA; Griffiths EA; Jabbour E; Garcia-Manero G; Rizzieri D; Stock W; Savona MR; Rosenblat TL; Berdeja JG; Ravandi F; Rock EP; Hao Y; Azab M; Issa JJ
Lancet Oncol; 2017 Oct; 18(10):1317-1326. PubMed ID: 28844816
[TBL] [Abstract][Full Text] [Related]
4. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study.
Falchi L; Ma H; Klein S; Lue JK; Montanari F; Marchi E; Deng C; Kim HA; Rada A; Jacob AT; Kinahan C; Francescone MM; Soderquist CR; Park DC; Bhagat G; Nandakumar R; Menezes D; Scotto L; Sokol L; Shustov AR; O'Connor OA
Blood; 2021 Apr; 137(16):2161-2170. PubMed ID: 33171487
[TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
Issa JJ; Roboz G; Rizzieri D; Jabbour E; Stock W; O'Connell C; Yee K; Tibes R; Griffiths EA; Walsh K; Daver N; Chung W; Naim S; Taverna P; Oganesian A; Hao Y; Lowder JN; Azab M; Kantarjian H
Lancet Oncol; 2015 Sep; 16(9):1099-1110. PubMed ID: 26296954
[TBL] [Abstract][Full Text] [Related]
6. Guadecitabine (SGI-110): an investigational drug for the treatment of myelodysplastic syndrome and acute myeloid leukemia.
Daher-Reyes GS; Merchan BM; Yee KWL
Expert Opin Investig Drugs; 2019 Oct; 28(10):835-849. PubMed ID: 31510809
[No Abstract] [Full Text] [Related]
7. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
Shi Y; Dong M; Hong X; Zhang W; Feng J; Zhu J; Yu L; Ke X; Huang H; Shen Z; Fan Y; Li W; Zhao X; Qi J; Huang H; Zhou D; Ning Z; Lu X
Ann Oncol; 2015 Aug; 26(8):1766-71. PubMed ID: 26105599
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.
Sébert M; Renneville A; Bally C; Peterlin P; Beyne-Rauzy O; Legros L; Gourin MP; Sanhes L; Wattel E; Gyan E; Park S; Stamatoullas A; Banos A; Laribi K; Jueliger S; Bevan L; Chermat F; Sapena R; Nibourel O; Chaffaut C; Chevret S; Preudhomme C; Adès L; Fenaux P;
Haematologica; 2019 Aug; 104(8):1565-1571. PubMed ID: 30733271
[TBL] [Abstract][Full Text] [Related]
9. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.
Damaj G; Gressin R; Bouabdallah K; Cartron G; Choufi B; Gyan E; Banos A; Jaccard A; Park S; Tournilhac O; Schiano-de Collela JM; Voillat L; Joly B; Le Gouill S; Saad A; Cony-Makhoul P; Vilque JP; Sanhes L; Schmidt-Tanguy A; Bubenheim M; Houot R; Diouf M; Marolleau JP; Béné MC; Martin A; Lamy T
J Clin Oncol; 2013 Jan; 31(1):104-10. PubMed ID: 23109692
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes.
Lee YG; Kim I; Yoon SS; Park S; Cheong JW; Min YH; Lee JO; Bang SM; Yi HG; Kim CS; Park Y; Kim BS; Mun YC; Seong CM; Park J; Lee JH; Kim SY; Lee HG; Kim YK; Kim HJ;
Br J Haematol; 2013 May; 161(3):339-47. PubMed ID: 23432512
[TBL] [Abstract][Full Text] [Related]
11. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.
Lübbert M; Suciu S; Baila L; Rüter BH; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Beeldens F; Muus P; Pflüger KH; Coens C; Hagemeijer A; Eckart Schaefer H; Ganser A; Aul C; de Witte T; Wijermans PW
J Clin Oncol; 2011 May; 29(15):1987-96. PubMed ID: 21483003
[TBL] [Abstract][Full Text] [Related]
12. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China.
Shi Y; Jia B; Xu W; Li W; Liu T; Liu P; Zhao W; Zhang H; Sun X; Yang H; Zhang X; Jin J; Jin Z; Li Z; Qiu L; Dong M; Huang X; Luo Y; Wang X; Wang X; Wu J; Xu J; Yi P; Zhou J; He H; Liu L; Shen J; Tang X; Wang J; Yang J; Zeng Q; Zhang Z; Cai Z; Chen X; Ding K; Hou M; Huang H; Li X; Liang R; Liu Q; Song Y; Su H; Gao Y; Liu L; Luo J; Su L; Sun Z; Tan H; Wang H; Wang J; Wang S; Zhang H; Zhang X; Zhou D; Bai O; Wu G; Zhang L; Zhang Y
J Hematol Oncol; 2017 Mar; 10(1):69. PubMed ID: 28298231
[TBL] [Abstract][Full Text] [Related]
13. A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.
Pellegrini C; Dodero A; Chiappella A; Monaco F; Degl'Innocenti D; Salvi F; Vitolo U; Argnani L; Corradini P; Zinzani PL;
J Hematol Oncol; 2016 Apr; 9():38. PubMed ID: 27071522
[TBL] [Abstract][Full Text] [Related]
14. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
15. [A preliminary study on the outcome of lower-risk myelodysplastic syndrome by low-dose decitabine].
Ye L; Ren YL; Xie LL; Luo YW; Lin PP; Zhou XP; Ma LY; Mei C; Xu WL; Wei JY; Jiang HF; Zhang LM; Zeng H; Tong HY
Zhonghua Xue Ye Xue Za Zhi; 2017 Apr; 38(4):307-312. PubMed ID: 28468092
[No Abstract] [Full Text] [Related]
16. A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer.
Albany C; Fazal Z; Singh R; Bikorimana E; Adra N; Hanna NH; Einhorn LH; Perkins SM; Sandusky GE; Christensen BC; Keer H; Fang F; Nephew KP; Spinella MJ
Cancer Med; 2021 Jan; 10(1):156-163. PubMed ID: 33135391
[TBL] [Abstract][Full Text] [Related]
17. Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study.
Fenaux P; Gobbi M; Kropf PL; Issa JJ; Roboz GJ; Mayer J; Krauter J; Robak T; Kantarjian H; Novak J; Jedrzejczak WW; Thomas X; Ojeda-Uribe M; Miyazaki Y; Min YH; Yeh SP; Brandwein J; Gercheva-Kyuchukova L; Demeter J; Griffiths E; Yee K; Döhner K; Hao Y; Keer H; Azab M; Döhner H
Blood Adv; 2023 Sep; 7(17):5027-5037. PubMed ID: 37276510
[TBL] [Abstract][Full Text] [Related]
18. Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine.
O'Connell CL; Baer MR; Ørskov AD; Saini SK; Duong VH; Kropf P; Hansen JW; Tsao-Wei D; Jang HS; Emadi A; Holmberg-Thyden S; Cowland J; Brinker BT; Horwood K; Burgos R; Hostetter G; Youngblood BA; Hadrup SR; Issa JP; Jones P; Baylin SB; Siddiqi I; Grønbaek K
Clin Cancer Res; 2022 Dec; 28(24):5306-5316. PubMed ID: 36222848
[TBL] [Abstract][Full Text] [Related]
19. Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia.
Chung W; Kelly AD; Kropf P; Fung H; Jelinek J; Su XY; Roboz GJ; Kantarjian HM; Azab M; Issa JJ
Clin Epigenetics; 2019 Jul; 11(1):106. PubMed ID: 31331399
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002).
Shi Y; Wu J; Wang Z; Zhang L; Wang Z; Zhang M; Cen H; Peng Z; Li Y; Fan L; Guo Y; Ma L; Cui J; Gao Y; Yang H; Zhang H; Wang L; Zhang W; Zhang H; Xie L; Jiang M; Zhou H; Shuang Y; Su H; Ke X; Jin C; Du X; Du X; Liu L; Xi Y; Ge Z; Feng R; Zhang Y; Zhou S; Xie F; Wang Q
J Hematol Oncol; 2021 Jan; 14(1):12. PubMed ID: 33436023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
